181 related articles for article (PubMed ID: 7515644)
1. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
Engelhard M; Gerhartz H; Brittinger G; Engert A; Fuchs R; Geiseler B; Gerhartz D; Haunauske AR; Hartlapp HJ; Huhn D
Ann Oncol; 1994; 5 Suppl 2():123-5. PubMed ID: 7515644
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas.
Gerhartz HH; Engelhard M; Meusers P; Brittinger G; Wilmanns W; Schlimok G; Mueller P; Huhn D; Musch R; Siegert W
Blood; 1993 Oct; 82(8):2329-39. PubMed ID: 7691256
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
Bergmann L; Karakas T; Knuth A; Lautenschläger G; Mitrou PS; Hoelzer D
Eur J Cancer; 1995 Dec; 31A(13-14):2164-8. PubMed ID: 8652236
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
Kaku K; Takahashi M; Moriyama Y; Nakahata T; Masaoka T; Yoshida Y; Shibata A; Kaneko T; Miwa S
Leuk Lymphoma; 1993 Oct; 11(3-4):229-38. PubMed ID: 8260897
[TBL] [Abstract][Full Text] [Related]
5. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Eur J Haematol; 1995 Aug; 55(2):88-92. PubMed ID: 7543059
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas.
Hovgaard D; Nissen NI
Leuk Lymphoma; 1992 Jun; 7(3):217-24. PubMed ID: 1477649
[TBL] [Abstract][Full Text] [Related]
7. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
[TBL] [Abstract][Full Text] [Related]
8. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
[TBL] [Abstract][Full Text] [Related]
9. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Engelhard M; Meusers P; Brittinger G; Brack N; Dornoff W; Enne W; Gassmann W; Gerhartz H; Hallek M; Heise J
Ann Oncol; 1991 Feb; 2 Suppl 2():177-80. PubMed ID: 1710919
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
Hovgaard DJ; Nissen NI
J Clin Oncol; 1992 Mar; 10(3):390-7. PubMed ID: 1740678
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with COP-BLAM III for intermediate and high-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Int J Hematol; 1994 Jul; 60(1):71-8. PubMed ID: 7522616
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas.
Gerhartz HH; Engelhard M; Brittinger G; Schlimok G; Thiel E; Huber C; Emmerich B; Schadek C; Brandmaier R; Stern AC
Semin Oncol; 1994 Dec; 21(6 Suppl 16):25-8. PubMed ID: 7528447
[No Abstract] [Full Text] [Related]
13. [Usefulness of COP-BLAM therapy with concomitant G-CSF in elderly patients with non-Hodgkin's lymphoma in comparison with patients not given G-CSF].
Niitsu N; Umeda M
Nihon Ronen Igakkai Zasshi; 1995 Jun; 32(6):410-5. PubMed ID: 7563935
[TBL] [Abstract][Full Text] [Related]
14. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
15. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA
J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
[TBL] [Abstract][Full Text] [Related]
16. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
Zinzani PL; Martelli M; Tura S; Mandelli F
Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
[TBL] [Abstract][Full Text] [Related]
18. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
19. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease.
Aglietta M; Montemurro F; Fagioli F; Volta C; Botto B; Cantonetti M; Racanelli V; Teofili L; Ferrara R; Amadori S; Castoldi GL; Dammacco F; Levis A
Cancer; 2000 Jan; 88(2):454-60. PubMed ID: 10640980
[TBL] [Abstract][Full Text] [Related]
20. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
